Patent US3856959A successfully refreshed from Google Patents.
US3856959A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Inhibition of leukemia utilizing 5-methyltetrahydrohomofolate
Assignee: DEPARTMENT OF HEALTH EDUCATION
•
Filing: 1972-07-24
•
Granted: 1974-12-24
•
Expires: 1992-07-24
Abstract
Abstract A method of inhibiting methotrexate sensitive leukemia L1210 and methotrexate resistant leukemias derived from L1210, such as variants L1210/FR-8, L1210/M-46-R, L1210/C-95, and L1210/M-66-3A in mice. This method produces optimum results as to the resistant leukemias as well as significant activity as to the sensitive leukemia. The compound employed is 5-methyltetrahydrohomofolate utilized as an injectable in a dosage regiment of 12.5-1600 mg/kg/inj/diem. The mechanism of action prefers dosages for at least two to four days, and in mice optimum results are obtained when treatment is commenced on day 1 following leukemia innoculation and is continued to the death of mice.
Inventors
- 👤 J Mead
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 17:54
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/505; A61P; A61P35/00; A61P35/02; C; C07; C07D; C07D475/00; C07D475/02; C07D475/04
Claims Analysis
Total Claims: 5
Claim 1
Independent Claim
21 words
A METHOD OF INHIBITING L1210 LEUKEMIA IN MICE WHICH CONSISTS OF INJECTING IN SAID MICE AN EFFECTIVE INHIBITION DOSAGE OF 5-METHYLTETRAHYDROHOMOFOLATE.
Claim 2
Independent Claim
21 words
A METHOD OF INHIBITING L1210 LEUKEMIA IN MICE WHICH CONSISTS OF INJECTING IN SAID MICE AN EFFECTIVE INHIBITION DOSAGE OF 5-METHYLTETRAHYDROHOMOFOLATE.
Claim 3
Independent Claim
36 words
A method of treating murine leukemia selected from the group consisting of L1210 and methotrexate resistant variants thereof in mice which comprises injecting in said mice about 12.5-1,600 mg/kg/inj/day for at least 2 days with 5-methyltetrahydrohomofolate.
Claim 4
Independent Claim
36 words
A method of treating murine leukemia selected from the group consisting of L1210 and methotrexate resistant variants thereof in mice which comprises injecting in said mice about 12.5-1,600 mg/kg/inj/day for at least 2 days with 5-methyltetrahydrohomofolate.
Claim 5
Dependent Claim
16 words
The method according to claim 2 which comprises treating methotrexate resistant variant of leukemias of L1210.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1977-12-23 | 1978-06-24 | 1978-12-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1981-12-23 | 1982-06-24 | 1982-12-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1985-12-23 | 1986-06-24 | 1986-12-24 | $7700.00 | Window Closed / Lapsed |